Schizophrenia
FDA approves first new class of schizophrenia treatment in more than 30 years
The FDA has approved Cobenfy, formerly known as KarXT, a muscarinic acetylcholine receptor agonist for the treatment of schizophrenia in adults.
Safety of TV-46000, long-acting injection for schizophrenia, consistent in phase 3 study
Among patients with schizophrenia, TV-46000 had a favorable safety profile that was consistent with other formulations of risperidone and previous studies of TV-46000, according to a study published in CNS Drugs.
Neurotransmitters and Neurobiology: Exploring the Mechanism of Action of Emerging Schizophrenia Treatments
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Brain stimulation may have distinct near-maximal effective doses across mental disorders
Significant dose-response associations were found for transcranial magnetic stimulation and transcranial direct current stimulation across several mental disorders, including schizophrenia and depression, according to research.
VIDEO: Co-occurring schizophrenia, stimulant use disorder ‘challenging’ to treat
NEW YORK — The prevalence of substance use disorders is high among patients with schizophrenia, Randall F. White, MD, said in this Healio Video Perspective from the American Psychiatric Association Annual Meeting.
One in five pregnant women report using CBD-only products
Twenty percent of pregnant women reported using CBD-only products during pregnancy despite limited available data on potential adverse outcomes of CBD, according to findings published in Obstetrics & Gynecology.
Positive efficacy results reported in phase 3 study of schizophrenia injectable
Teva Pharmaceuticals and Medincell have announced positive efficacy results from the phase 3 SOLARIS clinical trial evaluating an investigational, monthly subcutaneous injectable in adults with schizophrenia.
Q&A: Keto diet may improve symptoms of severe mental illness
Results of a small pilot study suggest that the ketogenic diet may help counter adverse metabolic effects of psychotropic medications and improve mental health among adults with schizophrenia or bipolar disorder.
Results positive in study of PDE4 inhibitor for cognitive impairment in schizophrenia
A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy volunteers of a novel PDE4 inhibitor being developed to treat those with cognitive impairment associated with schizophrenia.
Severe maternal morbidity raises risk for mental health hospitalizations, ED visits
Severe maternal morbidity was associated with increased risk for mental health hospitalization or emergency department visit up to 13 years postpartum, according to a population-based Canadian cohort study published in JAMA Network Open.